Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309484 | 0.91 | KMT2A (0.38) | SCDCYP3A4ALDH1A1 | |
| SCHEMBL13773615 | 0.91 | CYP3A4 (0.38) | CYP3A4ALDH1A1 | |
| SCHEMBL14310170 | 0.89 | HPGD (0.37) | CACNA1ICYP3A4CACNA1GCACNA1H | |
| SCHEMBL14309906 | 0.89 | CACNA1G (0.39) | CACNA1ICYP3A4CACNA1GCACNA1H | |
| SCHEMBL13773612 | 0.89 | MEN1 (0.47) | CACNA1ICYP3A4CACNA1GCACNA1HALDH1A1 | |
| SCHEMBL14308209 | 0.88 | CACNA1I (0.40) | ELANECACNA1IKCNH2HRH3SCD | |
| SCHEMBL14319229 | 0.88 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL14309968 | 0.88 | CLPP (0.35) | CYP3A4 | |
| SCHEMBL14308210 | 0.88 | KDM4E (0.35) | CYP3A4ALDH1A1 | |
| SCHEMBL13773704 | 0.88 | CCR5 (0.42) | CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957516-B1 | ALFA-HELIX MIMETICS AND METHOD RELATING TO THE TREATMENT OF CANCER STEM CELLS | CHOONGWAE PHARMA CORP (KR) | 2016-03-09 | — | — | EP | disclosed |
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | INSTITUTE FOR CHEMICAL GENOMICS | 2008-01-10 | — | — | US | disclosed |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009500-A1 | Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders | COL1A1, COL2A1, PLOD3 | ELANE 141/4885CACNA1I 4868/4885KCNH2 4626/4885 |
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | ELANE 3352/4885CACNA1I 4831/4885KCNH2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.